Solnerstotug (SNS-101)
Advanced solid tumors
Phase 1/2Completing trial
Key Facts
About Sensei Biotherapeutics
Sensei Biotherapeutics is a Boston-based, clinical-stage biotech focused on next-generation cancer therapeutics. Following a transformative 2024 acquisition, the company's strategy now centers on PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor combined with dietary intervention, representing a novel metabolic modulation approach. The company is also advancing solnerstotug, a VISTA-targeting immunotherapy, through Phase 1/2 trials. With a compact pipeline and a distressed public market valuation, Sensei represents a high-risk, high-potential turnaround story in the competitive oncology landscape.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |